Azienda Sanitaria Locale Napoli 1 Centro — Clinical Trial Site

24 Registered trials

12 Currently recruiting

Organisation

Azienda Sanitaria Locale Napoli 1 Centro

Location

Naples, Italy

Identifier

ORG-100046732

Address

Viala Delle Metamorfosi, 80147, Italy

Departments

#3612: U.O.S.D. Reumatologia
#4105: U.O.C. di Oncologia
3612: UOSD Reumatologia
93133024: U.O.C. di Oncologia (P.O. Ospedale del Mare)
Medical Oncology
n/a
Oncologia
Oncologia Medica
Oncology
P.O. Ospedale del Mare - UOC Oncologia Via Enrico Russo 11,- 80147 Napoli (Italy)
Radiotherapy
U.O.C Oncologia
U.O.C. Oncologia
U.O.C. Oncology
UOC di Oncologia
UOC Oncologia
UOC Oncologia - Ospedale del Mare
UOC Oncologia Medica

Clinical trials at this site (24)

Search interface

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carci… Pending

2025-521608-23-00 patients with unrestectable hepatocellular carcinoma (S 4
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting

2024-513077-48-00 O6-methylguanine methyltransferase (MGMT) unmethylated 5 2024-12-19
A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting

2023-504478-39-00 Squamous cell carcinoma of head and neck 5 2025-05-23
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo… Recruiting

2024-513550-30-00 Newly diagnosed Glioblastoma 5 2025-03-28
Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with… Recruiting

2024-515214-41-00 advanced pancreatic cancer 5 2025-03-27
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 colorectal metastatic cancer 4 2025-01-08
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
Regorafenib for recurrent meningioma. A multicenter, randomized phase II study (MIRAGE trial) Recruiting

2024-510954-28-01 grade 1, 2 and 3 meningioma 4 2024-09-23
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Ended

2023-504600-28-00 Metastatic Hepatocellular Carcinoma (HCC) 10 2024-05-09
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Hepatocellular Carcinoma 4 2024-03-01
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended

2022-502012-37-00 Advanced Hepatocellular Carcinoma 5 2023-10-06
Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended

2023-508499-12-00 Systemic Lupus Erythematosus 5 2023-05-17
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended

2024-511439-84-00 non-resectable hepatocellular carcinoma (HCC) 4 2023-03-30
Adjuvant therapy in stage IV colorectal cancer patients NED Ended

2024-518217-26-00 Stage IV colorectal cancer patients with no evidence of 4 2021-10-20
A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended

2023-503229-21-00 Unresectable hepatocellular carcinoma (HCC) 5 2021-05-06
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Solid tumours 9 2022-06-29
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 5 2019-05-20